Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - General

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Revenue projections:

Revenue projections for JNJ
Revenue projections for JNJ

Investors are expected to be cautious with JNJ, as its revenues are projected to fall compared to last year. A decline in revenue often results in a negative impact on profitability, prompting concerns about the company's financial stability and making investors more conservative in their approach.

Financial Ratios:

currentRatio 0.000000
forwardPE 18.131552
debtToEquity 60.499000
earningsGrowth -0.529000
revenueGrowth 0.099000
grossMargins 0.679970
operatingMargins 0.267230
trailingEps 11.030000
forwardEps 12.710440

JNJ's Forward PE is in a reasonable range, indicating the stock is priced well relative to its earnings. The stock isn't overpriced, which leaves room for future growth, making it an attractive option for investors seeking value and long-term gains.
JNJ's low earnings and revenue growth suggest that the company may face shrinking profits. This could indicate underlying financial challenges, making it difficult for JNJ to sustain its current profitability.
JNJ's positive gross and operating margins reflect strong profitability and operational efficiency. These metrics indicate the company's ability to control costs while maintaining healthy revenue, contributing to its solid financial performance.
Johnson & Johnson's forward EPS exceeding its trailing EPS means the company is expected to be more profitable this year than last. This suggests an upward trend in earnings, with forecasts indicating that Johnson & Johnson's financial performance will improve in the current financial year.

Price projections:

Price projections for JNJ
Price projections for JNJ

Price projections for JNJ have been revised upward over time, signaling increasing optimism about the company's future. This steady increase reflects a positive outlook for JNJ's growth and market performance.

Insider Transactions:

Insider Transactions for JNJ
Insider Transactions for JNJ


12 Johnson & Johnson shares were sold in recent transactions, with market price at 201.05833307902017.1 transactions to buy Johnson & Johnson occurred, with market price at 207.55999755859375.The higher volume of buys compared to sells near current Johnson & Johnson price levels may suggest optimism among investors. This could point to a favorable market outlook, as more people are willing to invest at these prices, anticipating potential future growth or strong performance.

Recommendation changes over time:

Recommendations trend for JNJ
Recommendations trend for JNJ


With analysts showing a buy bias for JNJ, investors may be more inclined to see the stock as an attractive investment. The favorable outlook could spur increased interest, positioning JNJ as a safe and profitable place for investors to allocate their funds and seek growth.